A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs BI 907828 (Primary)
- Indications Brain metastases; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 12 Jun 2019 11 patients (data cut off: 8 February 2019) have been enrolled as per trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Trial design of the study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2019 Planned End Date changed from 13 Jun 2023 to 20 Jan 2023.